Developing a proprietary drug to treat acute painful and debilitating attacks associated with 20 million patients suffering from chronic inflammatory conditions
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free